The effect of a two-week low glycaemic index, higher fibre diet versus high glycaemic index diet on body composition, ectopic lipids, inflammatory biomarkers, gastrointestinal hormones and gut microbiota in metabolic dysfunction-associated steatotic liver disease (MASLD): A pilot randomized cross-over study
Abstract
Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) is a global health concern. Low glycaemic index (LGI) diets, which tend to be naturally higher in dietary fibre, may reduce liver fat, blood glucose, and gut microbiota imbalance arresting MASLD progression. We hypothesized that in patients with MASLD, an LGI diet, meeting estimated energy requirements, would reduce liver fat more than a high GI (HGI) diet, despite matched energy (isoenergetic) and macronutrient content. To test this, a 2 × 2 randomized cross-over trial was undertaken involving 7 participants with MASLD randomised (1:1 ratio) to a 2-week either high GI (HGI) or LGI diet followed by a 4-week wash-out period and then the opposite diet. The impact of the LGI diet on liver fat content, measured using Magnetic Resonance Spectroscopy (1H-MRS) liver-related blood biomarkers, appetite (using subjective visual analogue scales) and gut microbiome composition was identified. Relative liver fat fraction was markedly reduced following the LGI diet (8.57%).Observations in the LGI group coincided with changes in blood glycaemic biomarkers, including a significant reduction in HOMA-IR (-1.78, p = 0.043). Additionally, the LGI diet resulted in significant reductions in body weight (-1.2 kg, p = 0.018) and body mass index (-0.38 kg/m2, p = 0.017), as well as increased pre-meal appetite scores during the middle of the diet period and decreased interleukin 6; IL-6 (-0.9 pg/mL) and glucagon (-13.7 pg/mL) levels…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 7 participants or records.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.